» Articles » PMID: 20538172

Cardiac Sympathetic Denervation Assessed with 123-iodine Metaiodobenzylguanidine Imaging Predicts Ventricular Arrhythmias in Implantable Cardioverter-defibrillator Patients

Abstract

Objectives: The purpose of this study was to evaluate whether 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging predicts ventricular arrhythmias causing appropriate implantable cardioverter-defibrillator (ICD) therapy (primary end point) and the composite of appropriate ICD therapy or cardiac death (secondary end point).

Background: Although cardiac sympathetic denervation is associated with ventricular arrhythmias, limited data are available on the predictive value of sympathetic nerve imaging with 123-I MIBG on the occurrence of arrhythmias.

Methods: Before ICD implantation, patients underwent 123-I MIBG and myocardial perfusion imaging. Early and late 123-I MIBG (planar and single-photon emission computed tomography [SPECT]) imaging was performed to assess cardiac innervation (heart-to-mediastinum ratio, cardiac washout rate, and 123-I MIBG SPECT defect score). Stress-rest myocardial perfusion imaging was performed to assess myocardial infarction and perfusion abnormalities (perfusion defect scores). During follow-up, appropriate ICD therapy and cardiac death were documented.

Results: One-hundred sixteen heart failure patients referred for ICD therapy were enrolled. During a mean follow-up of 23 +/- 15 months, appropriate ICD therapy (primary end point) was documented in 24 (21%) patients and appropriate ICD therapy or cardiac death (secondary end point) in 32 (28%) patients. Late 123-I MIBG SPECT defect score was an independent predictor for both end points. Patients with a large late 123-I MIBG SPECT defect (summed score >26) showed significantly more appropriate ICD therapy (52% vs. 5%, p < 0.01) and appropriate ICD therapy or cardiac death (57% vs. 10%, p < 0.01) than patients with a small defect (summed score </=26) at 3-year follow-up.

Conclusions: Cardiac sympathetic denervation predicts ventricular arrhythmias causing appropriate ICD therapy as well as the composite of appropriate ICD therapy or cardiac death.

Citing Articles

Diagnostic Efficacy of Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.

Hagen J, Scheifele M, Zacherl M, Katzdobler S, Bernhardt A, Brendel M Diagnostics (Basel). 2025; 15(1.

PMID: 39795552 PMC: 11720076. DOI: 10.3390/diagnostics15010024.


The Utility of Baseline Characteristics and [I]MIBG Cardiac Adrenergic System Scintigraphy in Qualifying Patients with Post-Infarction Heart Failure for Implantable Cardioverter-Defibrillator (ICD) Placement.

Teresinska A, Fronczak-Jakubczyk A, Wozniak O, Maciag A, Jezierski J, Cicha-Mikolajczyk A J Clin Med. 2024; 13(21).

PMID: 39518517 PMC: 11546305. DOI: 10.3390/jcm13216378.


Renal autonomic dynamics in hypertension: how can we evaluate sympathetic activity for renal denervation?.

Kusayama T, Nagamori Y, Takeuchi K, Nakagawa Y, Takamura M Hypertens Res. 2024; 47(10):2685-2692.

PMID: 39095482 DOI: 10.1038/s41440-024-01816-2.


Cardiac sympathetic activity and lethal arrhythmic events: insight into bell-shaped relationship between I-meta-iodobenzylguanidine activity and event rates.

Nakajima K, Nakata T, Doi T, Verschure D, Frantellizzi V, De Feo M EJNMMI Res. 2024; 14(1):67.

PMID: 39033243 PMC: 11264658. DOI: 10.1186/s13550-024-01131-4.


Cardiac sympathetic hyperinnervation after myocardial infarction: a systematic review and qualitative analysis.

Chen H, van Roon L, Schoones J, Zeppenfeld K, DeRuiter M, Jongbloed M Ann Med. 2023; 55(2):2283195.

PMID: 38065671 PMC: 10836288. DOI: 10.1080/07853890.2023.2283195.